Last reviewed · How we verify
Test formulation of HRS-1893 tablet
Test formulation of HRS-1893 tablet is a Small molecule drug developed by Shandong Suncadia Medicine Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Test formulation of HRS-1893 tablet |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test formulation of HRS-1893 tablet CI brief — competitive landscape report
- Test formulation of HRS-1893 tablet updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI
Frequently asked questions about Test formulation of HRS-1893 tablet
What is Test formulation of HRS-1893 tablet?
Test formulation of HRS-1893 tablet is a Small molecule drug developed by Shandong Suncadia Medicine Co., Ltd..
Who makes Test formulation of HRS-1893 tablet?
Test formulation of HRS-1893 tablet is developed by Shandong Suncadia Medicine Co., Ltd. (see full Shandong Suncadia Medicine Co., Ltd. pipeline at /company/shandong-suncadia-medicine-co-ltd).
What development phase is Test formulation of HRS-1893 tablet in?
Test formulation of HRS-1893 tablet is in Phase 1.